Swiss drugmaker Roche Holding AG said on Monday the European Union has approved the use of its drug RoActemra in patients with early-stage rheumatoid arthritis.
Roche said the European Commission has backed RoActemra as a treatment for patients with severe, active and progressive rheumatoid arthritis who have previously not been treated with methotrexate.
{iframe}http://www.reuters.com/article/2014/09/08/us-roche-pharmaceuticals-idUSKBN0H309O20140908{/iframe}